Abstract 445P
Background
Nasopharyngeal cancer (NPC) is notably prevalent in Southeast Asia, including Hong Kong. The survival rate of NPC patients has improved over the past decade. However, the emergence of various late radiation side effects during survivorship remains a concern. While the clinician-reported incidence of symptoms has been reported, a comprehensive assessment of self-reported symptoms is still lacking. This study aims to examine the subjective symptom burden, quality of life, and unmet needs among local NPC survivors.
Methods
A single-centre cross-sectional survey was conducted at a local public hospital, including 200 NPC survivors who had completed radiation therapy (RT) with or without chemotherapy for three to 120 months. We employed the Chinese version of three questionnaires: M. D. Anderson Symptom Inventory - Head & Neck Module (MDASI-HN), Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN), and Cancer Survivors’ Unmet Needs Measure (CaSUN).
Results
Survivors experienced, on average, more than four moderate to severe symptoms (Mean [M] ± SD = 4.84±4.99), with no association found with post-RT time (p = 0.443). The top five severe symptoms were dry mouth (M±SD = 5.47±2.90), mucus problem (M±SD = 4.27±3.17), dysphagia (M±SD = 3.38±3.03), teeth/gum problems (M±SD = 2.98±3.17), and poor memory (M±SD = 2.94±2.63). The mean scores of the top five symptoms were used to represent the symptom burden, which was negatively associated with the physical (F(1,198) = 139.783, p < 0.001, R2 = 0.414), emotional (F(2,197) = 38.303, p < 0.001, R2 = 0.280), additional concerns (F(1,198) = 85.993, p < 0.001, R2 = 0.303) subscales, and the total scores (F(2,197) = 33.083, p < 0.001, R2 = 0.251) of the FACT-HN. The unmet need for symptom management by CaSUN was positively associated with symptom burden (OR = 1.379, 95% CI [1.185, 1.604], p < 0.001), while negatively associated with post-RT time (OR = 0.981, 95% CI [0.972, 0.991], p < 0.001).
Conclusions
NPC survivors suffer from symptoms irrespective of the time elapsed post-RT. The observed varying unmet need for symptom management necessitates further exploration into supportive care for cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract